Clinical Commissioning Policy: Pasireotide diaspartate: an injectable medical therapy for the treatment of Cushings’ Disease

Document first published:
Page updated:
Topic:
,
Publication type:
This document describes the evidence that has been considered by NHS England in formulating a policy to routinely commission pasireotide diaspartate in the treatment of Cushing’s disease.

Document

clin-comm-pol-16052p

clin-comm-pol-16052p

  • PDF
  • 482 KB
  • 16 pages